Brussels, 2 September 2025 - A new policy review published in The Lancet Oncology and led by Ian Tannock and Madeline Pe, 1 together with an international team of oncologists, statisticians, patients and patient-reported outcomes (PRO) experts from Common Sense Oncology (CSO) and the European Organisation for Research and Treatment of Cancer (EORTC), emphasises the critical role of health-related quality of life (HRQoL) data in the evaluation of treatments for people with advanced cancer. This publication highlights the importance of having standardised responder criteria when evaluating HRQoL in clinical trials to improve patient care and clinical decision-making.
Key findings :
Focus on patient-centred outcomes: The paper highlights the need for clinical trials to evaluate HRQoL as at least a key secondary outcome for people with advanced cancer, alongside traditional clinical endpoints like overall survival. This approach evaluates whether new treatments not only extend life but also improve the quality of life for patients.
" Our goal is to ensure that the benefits of cancer treatments are fully understood, not just in terms of survival, but also in how they impact patients' day-to-day lives, " said Prof. Ian F. Tannock, co-lead author of the study. " By bringing oncologists, patient representatives, statisticians and PRO experts to the table, we were able to reach common ground on how the HRQoL results should be presented. This will allow oncologists to discuss with their patients the impact of treatments on quality of life, supporting shared decision-making, " added Dr Madeline Pe, co-lead author of the policy review and head of the EORTC Quality of Life Department.
" At EORTC, we strive to build global collaborations to drive progress in cancer research and patient care, including in the challenging situation of metastatic disease or non-resectable cancer. Our mission is to improve both the survival and quality of life of cancer patients, and we are proud to publish this new policy review encompassing some of the EORTC key priorities for the future, " concluded Prof. Winette van der Graaf, EORTC President and last author.
1 Ian F Tannock, Madeline Pe et al., Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer , The Lancet Oncology , Volume 26, Issue 9,2025, Pages e499-e507, ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(25)00288-8 .
About EORTC
The European Organisation for Research and Treatment of Cancer (EORTC) is a non-governmental, non-profit organisation, which unites clinical cancer research experts, throughout Europe, to define better treatments for cancer patients to prolong survival and improve quality of life. Spanning from translational to large, prospective, multi-centre, phase III clinical trials that evaluate new therapies and treatment strategies as well as patient quality of life, its activities are coordinated from EORTC Headquarters, a unique international clinical research infrastructure, based in Brussels, Belgium.
About the EORTC Quality of Life Group
The EORTC Quality of Life Group (QLG) strives to improve health-related quality of life (HRQoL) of cancer patients, through dedicated research and the use of HRQoL measures within cancer clinical trials and clinical practice. HRQoL constitutes an important aspect of cancer research and care: it gives a voice to patients, putting their experience at the forefront. The QLG is part of the European Organisation for Research and Treatment of Cancer (EORTC).
About CSO
Common Sense Oncology (CSO) is a global network of oncologists, researchers, patient-advocates, policy makers, and other stakeholders. We believe that patients should have equitable access to cancer treatments that provide meaningful improvements in outcomes, irrespective of where they live. CSO works collaboratively with people who have lived experience, organizations in the cancer field, and regulators to ensure that the outcomes that matter to patients and the public are at the centre of cancer research, cancer care delivery, and cancer systems policy.
The Lancet Oncology
Literature review
People
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer
1-Sep-2025
BG reports consulting fees from VIVIO Health. NIC reports stock options in Canopy Care. EAE reports honoraria from membership of a Data Safety and Monitoring Committee for DualityBio. GRP reports consulting fees from Profound Medical, Merck, AstraZeneca, and Takeda, and has a close family member who is employed by and holds stock in Roche. SFO reports grants from Novartis, Celldex Therapeutics, and Merck (paid to the institution); consultancy fees from Bristol Myers Squibb, GenMab, and Johnson & Johnson (paid to the institution); speakers bureau for Merck and Travel Congress Management BV (paid to the institution); and is a member of a steering and safety monitoring committee for ALX Oncology (unpaid). WTAdvG received a research grant from Eli Lilly with institutional payment. MB received a research grant from Pfizer with institutional payment. All other authors declare no competing interests.